^
    Back
    Association details:
    Biomarker:ROS1 rearrangement
    Cancer:Non Small Cell Lung Cancer
    Drug:Augtyro (repotrectinib) (ALK inhibitor, Multi-tyrosine kinase inhibitor, ROS1 inhibitor, Trk inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A2 - Guideline
    Source:
    NCCN
    Published date:
    12/21/2023
    Excerpt:
    Non-Small Cell Lung Cancer: ROS1 Rearrangement…First-line therapy...Repotrectinib…